Insomnia - Pipeline Review, H2 2020

Insomnia - Pipeline Review, H2 2020


latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2020, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Insomnia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 9, 7, 6, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 


Introduction
Insomnia - Overview
Insomnia - Therapeutics Development
Insomnia - Therapeutics Assessment
Insomnia - Companies Involved in Therapeutics Development
Insomnia - Drug Profiles
Insomnia - Dormant Projects
Insomnia - Discontinued Products
Insomnia - Product Development Milestones
Appendix
 


List Of Tables


Number of Products under Development for Insomnia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Insomnia - Pipeline by Amherst Pharmaceuticals LLC, H2 2020
Insomnia - Pipeline by Artelo Biosciences Inc, H2 2020
Insomnia - Pipeline by Biohemp International Inc, H2 2020
Insomnia - Pipeline by Cannabis Science Inc, H2 2020
Insomnia - Pipeline by Cennerv Pharma (S) Pte Ltd, H2 2020
Insomnia - Pipeline by Ci Therapeutics, H2 2020
Insomnia - Pipeline by Eisai Co Ltd, H2 2020
Insomnia - Pipeline by EUSOL Biotech Co Ltd, H2 2020
Insomnia - Pipeline by Evotec SE, H2 2020
Insomnia - Pipeline by Grupo Ferrer Internacional SA, H2 2020
Insomnia - Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, H2 2020
Insomnia - Pipeline by Idorsia Pharmaceutical Ltd, H2 2020
Insomnia - Pipeline by Imbrium Therapeutics LP, H2 2020
Insomnia - Pipeline by Intra-Cellular Therapies Inc, H2 2020
Insomnia - Pipeline by Johnson & Johnson, H2 2020
Insomnia - Pipeline by Linnet BioPharmaceuticals Inc, H2 2020
Insomnia - Pipeline by M et P Pharma AG, H2 2020
nsomnia - Dormant Projects, H2 2020
Insomnia - Discontinued Products, H2 2020
 


List Of Figures


Number of Products under Development for Insomnia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
 


Insomnia - Pipeline Review, H2 2020

Insomnia - Pipeline Review, H2 2020 latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2020, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.Insomnia

USD 2000 View Report

COVID-19 Outbreak-Global Insomnia Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

The Insomnia Drugs market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak globally, this

USD 3660 View Report

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2

USD 3500 View Report

Soluble Guanylate Cyclase - Pipeline Review, H2 2020

Soluble Guanylate Cyclase - Pipeline Review, H2 2020Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by

USD 3500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available